bioMérieux - First-Quarter 2015 Business Review

Strong growth in sales

• €448 million in sales

• Up 20.8% as reported

• Up 8.7% at constant exchange rates and scope of consolidation

• Sales off to a fast start in the Americas, up 19.6%*

Strengthened positions in priority areas for growth

• FilmArray®: sales almost doubled, reinforcing BioFire's leadership in the molecular and syndromic diagnosis of infectious diseases

• Clinical microbiology: robust 4.8%* growth

• VIDAS® immunoassays: sustained strong growth, up 8.7%*

• Industrial applications: firm upward trend, with a 5.6%* increase

2015 objective: faster organic* sales growth, confirmed at between 4.5% and 6.5%

Alexandre Mérieux, Chief Executive Officer, said: "In the first quarter of 2015, bioMérieux once again demonstrated the solidity of its growth model. Led by all the applications and the robust momentum in the Americas, organic growth in sales ended the period at 8.7%, exceeding our annual target. In particular, BioFire Diagnostics delivered 93% organic growth, attesting to FilmArray®'s market success in North America and the medical value of the syndromic diagnosis of infectious diseases. In addition, we stepped up our sales performance in clinical microbiology, where we are the global market leader. Backed by a vigorous start to the year, we are confirming our objective of organic growth in sales in 2015, while actively pursuing the operating projects designed to drive sustainable and profitable growth in our business."